menu
    • menu

    Company profile for OncoZenge

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OncoZenge is a Swedish pharmaceutical company founded in 2020 through a collaboration between Moberg Pharma AB and leading clinics from Hvidovre Hospital in Denmark.Our vision is to radically improve the quality of life for patients with severe oral pain, for example caused by radiation therapy or chemotherapy for cancer. Oncozenge develops better products for supportive care of cancer patients. In the near future, we will fo...
    OncoZenge is a Swedish pharmaceutical company founded in 2020 through a collaboration between Moberg Pharma AB and leading clinics from Hvidovre Hospital in Denmark.Our vision is to radically improve the quality of life for patients with severe oral pain, for example caused by radiation therapy or chemotherapy for cancer. Oncozenge develops better products for supportive care of cancer patients. In the near future, we will focus on preparing a phase 3 study for BupiZenge®. This after strong phase 2 results which showed that the pain level in the patients decreased by 50% compared to standard treatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncoZengeSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Gustavslundsvägen 34, 167 51 Bromma
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncozenge.se/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OncoZenge AB Collaborates with UCLA for BupiZenge™ Patient
    OncoZenge AB Collaborates with UCLA for BupiZenge™ Patient

    17 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncozenge-ab-enters-into-collaboration-with-ucla-for-patient-engagement-study-on-bupizenge-302558884.html

    PR NEWSWIRE
    17 Sep 2025
    Share Share
    OncoZenge Selects LINK Medical for BupiZenge Phase III Execution
    OncoZenge Selects LINK Medical for BupiZenge Phase III Execution

    11 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-11/oncozenge-ab-appoints-link-medical-as-cro-for-bupizenge-phase-iii-execution

    PHARMAWEB
    11 Sep 2025
    Share Share
    OncoZenge AB's Interim Report: Jan 1 - June 30, 2025
    OncoZenge AB's Interim Report: Jan 1 - June 30, 2025

    21 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-21/oncozenge-ab-interim-report-january-1-june-30-2025

    PHARMAWEB
    21 Aug 2025
    Share Share
    OncoZenge Enters SEK 30.2M Investment Agreement With Yangtian
    OncoZenge Enters SEK 30.2M Investment Agreement With Yangtian

    28 Jan 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-01-28/oncozenge-enters-into-sek-302-million-investment-agreement-with-new-strategic-investor-sichuan-yangtian-bio-pharmaceutical-intended-to-be-carried-out-through-directed-share-issues

    PHARMAWEB
    28 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search